A Chimeric Multi-epitope DNA Vaccine Elicited Specific Antibody Response Against Severe Acute Respiratory Syndrome-associated Coronavirus Which Attenuated the Virulence of SARS-CoV in Vitro

Overview

Journal Immunol Lett

Specialty Allergy & Immunology

Date 2008 Jun 6

PMID 18533276

Citations 16

Authors

Xiaohua Wang

Wei Xu

Deyan Tong

Jing Ni

Haifeng Gao

Ying Wang

Yiwei Chu

Pingping Li

Xiaoming Yang

Sidong Xiong

Affiliations

Soon will be listed here.

Abstract

Epitope-based vaccines designed to induce antibody responses specific for severe acute respiratory syndrome-associated coronavirus (SARS-CoV) are being developed as a means for increasing vaccine potency. In this study, we identified four B cell epitopes from the spike (S) and membrane (M) protein through bioinformatics analysis and constructed a multi-epitope DNA vaccine. Intramuscular immunization of mice with this vaccine was sufficient to induce specific prime as well as a long-term memory humoral immune response to at least two candidate epitopes, S(437-459) and M(1-20). A DNA prime-protein boost strategy greatly enhanced the antibody generation and the immune sera not only reacted with the lysates of SARS-CoV-infected Vero cells but also neutralized the cytopathic effect of SARS by 75% at 1:160 dilution. The novel immunogenic S protein peptide revealed in this study provides new target for SARS vaccine design; and our work indicated multi-epitope DNA vaccine as an effective means for eliciting polyvalent humoral immune response against SARS-CoV.

Citing Articles

Review on Approved and Inprogress COVID-19 Vaccines.

Farnudian-Habibi A, Mirjani M, Montazer V, Aliebrahimi S, Katouzian I, Abdolhosseini S Iran J Pharm Res. 2022; 21(1):e124228.

PMID: 36060923 PMC: 9420219. DOI: 10.5812/ijpr.124228.

Clinical and experimental bacteriophage studies: Recommendations for possible approaches for standing against SARS-CoV-2.

Shahin K, Zhang L, Mehraban M, Collard J, Hedayatkhah A, Mansoorianfar M Microb Pathog. 2022; 164:105442.

PMID: 35151823 PMC: 8830156. DOI: 10.1016/j.micpath.2022.105442.

Development of an Enzyme-Linked Immunosorbent Assay (ELISA) for Accurate and Prompt Coronavirus Disease 2019 (COVID-19) Diagnosis Using the Rational Selection of Serological Biomarkers.

Lagousi T, Routsias J, Spoulou V Diagnostics (Basel). 2021; 11(11).

PMID: 34829317 PMC: 8618656. DOI: 10.3390/diagnostics11111970.

Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and Convalescent Phase of COVID-19.

Jorrissen P, Schutz P, Weiand M, Vollenberg R, Schrempf I, Ochs K Front Immunol. 2021; 12:679841.

PMID: 34421894 PMC: 8371319. DOI: 10.3389/fimmu.2021.679841.

A comparative study of human betacoronavirus spike proteins: structure, function and therapeutics.

Verma J, Subbarao N Arch Virol. 2021; 166(3):697-714.

PMID: 33483791 PMC: 7821988. DOI: 10.1007/s00705-021-04961-y.

References

Xiong S, Gerloni M, Zanetti M . In vivo role of B lymphocytes in somatic transgene immunization. Proc Natl Acad Sci U S A. 1997; 94(12):6352-7. PMC: 21053. DOI: 10.1073/pnas.94.12.6352. View

Weiss S, Navas-Martin S . Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005; 69(4):635-64. PMC: 1306801. DOI: 10.1128/MMBR.69.4.635-664.2005. View

Hovanessian A, Briand J, Said E, Svab J, Ferris S, Dali H . The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection. Immunity. 2004; 21(5):617-27. DOI: 10.1016/j.immuni.2004.08.015. View

Zhi Y, Wilson J, Shen H . SARS vaccine: progress and challenge. Cell Mol Immunol. 2005; 2(2):101-5. View

Hofmann H, Hattermann K, Marzi A, Gramberg T, Geier M, Krumbiegel M . S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol. 2004; 78(12):6134-42. PMC: 416513. DOI: 10.1128/JVI.78.12.6134-6142.2004. View

Zhang H, Wang G, Li J, Nie Y, Shi X, Lian G . Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol. 2004; 78(13):6938-45. PMC: 421668. DOI: 10.1128/JVI.78.13.6938-6945.2004. View

Wolff J, Ludtke J, Acsadi G, Williams P, Jani A . Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet. 1992; 1(6):363-9. DOI: 10.1093/hmg/1.6.363. View

Li F, Li W, Farzan M, Harrison S . Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005; 309(5742):1864-8. DOI: 10.1126/science.1116480. View

Yu H, Jiang L, Fang D, Yan H, Zhou J, Zhou J . Selection of SARS-coronavirus-specific B cell epitopes by phage peptide library screening and evaluation of the immunological effect of epitope-based peptides on mice. Virology. 2006; 359(2):264-74. PMC: 7103350. DOI: 10.1016/j.virol.2006.09.016. View

10.

Ochsenbein A, Pinschewer D, Sierro S, Horvath E, Hengartner H, Zinkernagel R . Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs. Proc Natl Acad Sci U S A. 2000; 97(24):13263-8. PMC: 27213. DOI: 10.1073/pnas.230417497. View

11.

Wilson C, McKinney D, Anders M, MaWhinney S, Forster J, Crimi C . Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1. J Immunol. 2003; 171(10):5611-23. DOI: 10.4049/jimmunol.171.10.5611. View

12.

Depla E, Van der Aa A, Livingston B, Crimi C, Allosery K, De Brabandere V . Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections. J Virol. 2007; 82(1):435-50. PMC: 2224390. DOI: 10.1128/JVI.01505-07. View

13.

Hua R, Wang Y, Bu Z, Zhou Y, Ge J, Wang X . Identification and antigenic epitope mapping of immunodominant region amino residues 510 to 672 on the spike protein of the severe acute respiratory syndrome coronavirus. DNA Cell Biol. 2005; 24(8):503-9. DOI: 10.1089/dna.2005.24.503. View

14.

Voss D, Kern A, Traggiai E, Eickmann M, Stadler K, Lanzavecchia A . Characterization of severe acute respiratory syndrome coronavirus membrane protein. FEBS Lett. 2006; 580(3):968-73. PMC: 7094741. DOI: 10.1016/j.febslet.2006.01.026. View

15.

Kotsopoulou E, Kim V, Kingsman A, Kingsman S, Mitrophanous K . A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol. 2000; 74(10):4839-52. PMC: 112007. DOI: 10.1128/jvi.74.10.4839-4852.2000. View

16.

He Y, Zhou Y, Siddiqui P, Niu J, Jiang S . Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. J Clin Microbiol. 2005; 43(8):3718-26. PMC: 1234014. DOI: 10.1128/JCM.43.8.3718-3726.2005. View

17.

Zhang J, Chen J, Liu Y, Zhang Z, Gao H, Liu Y . A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol. 2005; 77(2):147-50. PMC: 7167078. DOI: 10.1002/jmv.20431. View

18.

Wong S, Li W, Moore M, Choe H, Farzan M . A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem. 2003; 279(5):3197-201. PMC: 7982343. DOI: 10.1074/jbc.C300520200. View

19.

Liang M, Du R, Liu J, Li C, Zhang Q, Han L . SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity. Biomed Environ Sci. 2006; 18(6):363-74. View

20.

Ho T, Wu S, Chen J, Wei Y, Cheng S, Chang Y . Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2005; 69(2):70-6. PMC: 7114127. DOI: 10.1016/j.antiviral.2005.10.005. View